Heart Test Laboratories (NASDAQ:HSCS – Get Free Report) posted its earnings results on Monday. The company reported ($2.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.30) by $0.03, Zacks reports. During the same period in the prior year, the firm earned ($15.92) earnings per share.
Heart Test Laboratories Trading Up 2.2 %
NASDAQ:HSCS opened at $3.85 on Tuesday. Heart Test Laboratories has a 12 month low of $2.36 and a 12 month high of $18.50. The company has a current ratio of 4.49, a quick ratio of 4.02 and a debt-to-equity ratio of 0.08. The company has a 50-day moving average price of $3.25 and a 200-day moving average price of $3.80. The stock has a market cap of $3.52 million, a price-to-earnings ratio of -0.18 and a beta of 3.23.
Analysts Set New Price Targets
Separately, Ascendiant Capital Markets reiterated a “buy” rating and issued a $15.00 price objective on shares of Heart Test Laboratories in a research report on Monday, September 23rd.
About Heart Test Laboratories
Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.
See Also
- Five stocks we like better than Heart Test Laboratories
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Why Costco’s Rally May Continue Into 2025
- What Are Some of the Best Large-Cap Stocks to Buy?
- 3 Growth Stocks to Grab for Less Than $100
- What is a SEC Filing?
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
Receive News & Ratings for Heart Test Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heart Test Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
